IBSRELA (tenapanor hydrochloride) by Ardelyx is sodium/hydrogen exchanger 3 (nhe3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. Approved for irritable bowel syndrome with constipation (ibs-c) in adults. First approved in 2019.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
IBSRELA (tenapanor hydrochloride) is an oral small-molecule NHE3 inhibitor approved in 2019 for irritable bowel syndrome with constipation (IBS-C) in adults. It works by blocking sodium-hydrogen exchange in the small intestine and colon, increasing water secretion into the intestinal lumen to accelerate transit and soften stool while reducing abdominal pain through decreased visceral hypersensitivity.
Product is at peak commercial maturity with stable Part D uptake of ~15,500 claims annually; brand team size likely moderate and focused on market maintenance rather than expansion.
sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. In vitro and animal studies indicate its major metabolite, M1, is not active against NHE3. By inhibiting NHE3 on the apical…
Worked on IBSRELA at Ardelyx? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on IBSRELA offers exposure to specialty pharma commercialization in a niche gastroenterology market with established payer relationships and stable patient populations. The peak lifecycle stage and modest team size suggest individual contributors will have clear ownership and direct impact on commercial metrics.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo